Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment

摘要: Reactivation of chronic hepatitis B virus (HBV) infection in patients undergoing chemotherapy is well-documented, but reactivation during imatinib mesylate treatment has not been reported. This study reports a 54-year-old man, without prior liver dysfunction with HBV infection, whom fatal occurred myeloid leukemia (CML) mesylate. He developed fulminant followed by marked elevation DNA polymerase, probably from the lymphocytopenic and immunosuppressive status induced Imatinib widely used to treat CML patients. Although therapy generally well tolerated, case presented here suggests that viral should be considered, even when using CML.